AIM Rule 26

The following information is being disclosed for the purposes of Rule 26 of the AIM Rules for Companies.

About ImmuPharma

Please click below for a description of the business.

About Us
Portfolio

Country of Incorporation and Main Country of Operation

Country of Incorporation: England and Wales
Company Registration Number: 3929567
Main Country of Operation: France

Registered Office

50 Broadway, London SW1H 0RG, UK

Corporate Governance
Please click below for details of ImmuPharma’s Corporate Governance procedure
Corporate Governance

Company Reports

Annual Report and Accounts 2016

Click on the link above for the Immupharma plc Annual Report 2016 .

Please note the file may take a few minutes to open.

It is recommended you save the report on your hard drive; right click on the photo and choose “Save As” and then save it on your computer before you open it.

Annual Report December 2015
Annual Report December 2014
Annual Report December 2013
Annual Report December 2012
Annual Report December 2011
Annual Report December 2010
Annual Report December 2009
Annual Report December 2008
Annual Report December 2007
Annual Report March 2006

Latest Interim Report

Interim Results June 2017

Notifications

NOTICE OF ANNUAL GENERAL MEETING ON 30 JUNE 2017 @ 10.30 AM

Investor presentation to follow at 11.30am
Venue: Sky Light City, 50 Basinghall Sreet, London, EC2

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company confirms that today the Annual Report and Accounts for the year ended 31 December 2016 has today been posted to shareholders.
This report includes the ‘Annual Report of the Annual General Meeting’ (‘AGM’) as well as the ‘Notice of the 2017 AGM’, which is available in electronic form, for download on the Company’s website www.immupharma.co.uk

ImmuPharma’s AGM will be held on Friday 30 June at 10:30am at Sky Light City Tower, 50 Basinghall Street, EC2V 5DE.

Investor Meeting @ 11.30am on 30 June 2017

ImmuPharma has confirmed that it will be hosting an Investor Presentation and luncheon immediately following the Company’s Annual General Meeting at 11.30am. Please contact Lisa Baderoon at lisa.baderoon@immupharma.com if you would like to attend this event.

Advisers

Nominated Adviser & Broker
Northland Capital Partners Ltd, 60 Gresham St, London EC2V 7BB
Tel +44 20 3861 6625

Public and Investor Relations
Lisa Baderoon
lisa.baderoon@immupharma.com
investors@immupharma.com

Solicitors
Bircham Dyson Bell, 50 Broadway, London SW1H 0BL, UK

Auditors
Nexia Smith & Williamson Chartered Accountants
25 Moorgate London EC2R 6AY, UK

Principal Bankers
Royal Bank of Scotland plc
62/63 Threadneedle Street, London EC2R 8LA, UK

Registrars
Computershare Investor Services PLC, PO Box 82, The Pavilions, Bridgewater Road, Bristol, BS99 7NH, UK

Current Constitutional Documents

Please click below for details of current constitutional documents.

Constitutional documents

For all notifications, please check the Regulatory News section.

Details of Any Other Exchanges or Trading Platforms

The Company’s shares are also traded in Germany. ‘Tradegate’ which is an open market listing on the Berlin Exchange and the ‘third segment’ of the Stuttgart Stock Exchange.

Number of Securities In Issue and Significant Shareholders

ImmuPharma has 132,522,985 ordinary shares of 10p each in issue, each of which entitles the holder to cast one vote in general meetings.  The company does not hold any Ordinary Shares in treasury.  The Company is not aware of any interest of 3% or more in the share capital of the Company other than the persons noted below.

Number of Ordinary 10p shares % of issued share capital
*Total ImmuPharma plc Directors 29,071,308 21.94%
Hargreaves Lansdown plc 10,906,974 8.23%
Aviva plc 10,228,926 7.72%
Landstead Investors 5,996,547 4.52%
Alto Invest 5,802,317 4.38%
Interactive Investor Trading 4,900,367 3.70%
Lloyds Banking Group 4,257,597 3.21%
Walker Crips group 3,383,869 2.55%
Legal and General Group 3,270,531 2.47%
Barclays Bank 2,848,683 2.15%
Total Issued Share Capital 132,522,985 43.03%
*The breakdown of the Director’s holding is:
Robert Zimmer
(President and Chief Science Officer)
25,344,514 19.12%
Dimitri Dimitriou
(Chief Executive Officer and Co-founder)
3,567,430 2.69%
Franco di Muzio
(Senior Non-Executive Director)
99,412 0.08%
Tim McCarthy
(Non-Executive Chairman)
38,462 0.03%
Dr Stéphane Méry
(Non-Executive Director)
21,490 0.02%

As far as the Company is aware, the percentage of ImmuPharma’s issued share capital that is not in public hands is just over 22%.  This percentage comprises the holdings of Directors only.

Details of any restrictions on the transfer of securities

There are no restrictions on the transfer of securities.

Circulars, Proxy Forms and Admission Document 

Please click on the link below to access the Company’s Proxy Form
IMM Proxy Form: Annual General Meeting to be held on 30 June 2017

Please click on the link below to access the Company’s circulars
IMM Circular February 2016 Fundrasing

Please click on the link below to access the Company’s Proxy Forms
IMM Proxy Form February 2016 Fundraising

Please click on the link below to access the Company’s Admission Document (January 2006).
ImmuPharma Admission Document

Special rules apply when US persons (as defined in the United States securities laws) access this website. For US regulatory reasons, US residents and other US persons who reside outside the United States are not permitted to access this website.  The company is not offering any securities or services in the United States or to residents of the United States through this website or otherwise.  Please refer to our Disclaimer.

Last Updated: 29/09/2017